Who can pay for innovative medicines?

A Framework for Understanding Ethical and Efficiency Issues in Pharmaceutical Intellectual Property Litigation

“…Gleevec is one example of how public investments resulted in private gains and profits. Not only is pharmaceutical research publicly funded, but also the major consumer of drugs manufactured by pharmaceutical companies is governments (Decramer and Decramer 2013). …”

Reaching the golden milestone. The 2013 ERS Dublin summit: preparing the road to Rome

“…Public-private partnerships are needed if we are to make new discoveries and advance the science of respiratory medicine. If we are to be successful, we need to foster more large-scale industry collaboration and engagement with the scientific community, promote more active involvement of patients, regulators and payers, and enable innovation via joint effort rather than alone [9].…”